Board Member
Niagen Bioscience, Inc. (NAGE)Chairman
Niagen Bioscience, Inc. (NAGE)Equibles does not estimate personal net worth.
Get an email with a short summary when Niagen Bioscience, Inc. publishes a filing, an earnings call transcript or a press release.
Get NAGE alertsFrank Jaksch is recorded as Board Member and Chairman at Niagen Bioscience, Inc. (NAGE) since January 1, 2000. The newest filing on record that lists Frank Jaksch as Board Member at Niagen Bioscience, Inc. (NAGE) is dated April 29, 2026. The newest filing on record that lists Frank Jaksch as Chairman at Niagen Bioscience, Inc. (NAGE) is dated April 27, 2022. The proxy statement of Niagen Bioscience, Inc. reports total compensation of $482,354 for Frank Jaksch in fiscal 2022, including a base salary of $223,984. Disclosed compensation is on record for 4 fiscal years. Frank Jaksch has spoken on 8 earnings calls across 1 company, most recently for Niagen Bioscience, Inc. on May 12, 2022. Niagen Bioscience, Inc. is classified in the Packaged Foods industry within the Consumer Defensive sector. Other leadership on record at Niagen Bioscience, Inc. includes Robert Fried (CEO and Board Member), James Lee (CFO and Chief Accounting Officer), Ozan Pamir (CFO and Chief Accounting Officer) and 7 others.
“We're seeing increases in organic searches and new website visitors, growth in new customers on our own site, as well as strong trends on Amazon.”
“Since our last update, there were several exciting preclinical publications on NR. I'll briefly highlight two.”
“In the second quarter, there were several preclinical publications on nicotinamide riboside, or NR, including studies on bone health, alcohol-induced inflammation and neuroinflammation.”
“As I mentioned in our last call, the research on nicotinamide riboside, or NR, continues to extend to important areas of human health.”
“2021 is setting up to be an exciting year for ChromaDex. Eleven peer-reviewed published clinical studies to date have validated the safety and/or efficacy of nicotinamide riboside, or NR, as an NAD precursor.”
2000-01-01–present
Last confirmed April 29, 2026
2000-01-01–present
Last confirmed April 27, 2022
Packaged Foods · Consumer Defensive
Board Member, Chairman
2000-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Niagen Bioscience, Inc. (NAGE) | Former Executive Chairman, Current Chairman of the Board | $223,984 | $482,354 |
| 2021 | Niagen Bioscience, Inc. (NAGE) | Former Executive Chairman, Current Chairman of the Board | $381,100 | $694,559 |
| 2020 | Niagen Bioscience, Inc. (NAGE) | Former Executive Chairman, Current Chairman of the Board | $398,758 | $734,678 |
| 2019 | Niagen Bioscience, Inc. (NAGE) | Executive Chairman | $378,111 | $636,778 |
